Matching slides 303,780
Current window 211,801-211,830
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

211,801-211,830 of 303,780

filter-aware
25
The slide uses a process flow diagram to align specific collaboration areas (target discovery, clinical trial recruitment, patient cohorts, disease awareness) with the drug development lifecycle.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
26
The slide features a photo of the team in front of a 23andMe building.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
27
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
30
Includes a Manhattan plot and a zoomed-in regional association plot.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
31
The left side shows Manhattan plots for Osteoarthritis over time (2016, 2017, 2021). The right side shows a line chart of total independent hits from 2015 to 2020.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
32
The slide displays a grid of heatmaps/data tables for different medical categories, with a specific example for NAFLD at the bottom.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
33
The slide uses Manhattan plots to show genetic associations with asthma, connected to a biological pathway diagram.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
34
The heatmap shows log(OR) values for three TSLP GWAS signals across various conditions.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
35
The slide uses a gradient bar chart to represent the progression of drug development programs.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
36
Uses a funnel framework to show the narrowing of research from broad data to specific targets.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
37
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
38
The slide uses a process flow to connect market size to proprietary methodology and specific pipeline assets.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
39
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
40
The slide uses heatmaps to show genetic associations, contrasting immune and cancer phenotypes for specific proteins.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
41
Includes a biological pathway diagram illustrating the interaction between tumor cells and immune cells.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
42
The slide uses a before-and-after diagram to illustrate the mechanism of action.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
43
The chart shows a scatter plot with a regression line indicating a correlation coefficient (rho) of 0.86.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
45
The slide uses a process flow diagram to illustrate the study design (Part A to Part B).23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
46
The slide outlines the mechanism of action, clinical rationale, and upcoming Phase 2a study design for the drug candidate.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
47
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
48
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
49
The slide features a gradient background with scattered DNA base letters (A, T, C, G) and a large number '5' in a circle, indicating it is the fifth section.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
50
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
51
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
52
Fiscal year ends March 31.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
53
Includes a callout highlighting the growth in Therapeutics R&D investment.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
54
Balances may not add up due to rounding.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
55
The background features scattered DNA base pairs (A, T, C, G), suggesting a biotech or genomics context.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
56
Uses a linguistic analogy to explain genetic imputation.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
57
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit